Arun Balakumaran
- Oncology top 0.5%
- Bone health and treatments 20
- Cancer Immunotherapy and Biomarkers 14
- CAR-T cell therapy research 13
- Cancer Diagnosis and Treatment 8
-
- Lymphoma Diagnosis and Treatment 29
- Immunology top 5%
- Genetics top 2%
- Mesenchymal stem cell research 9
- Hematology top 2%
- Multiple Myeloma Research and Treatments 9
-
- Management of metastatic bone disease 13
- Co-authors
- Pier Luigi ZinzaniMargaret A. ShippCraig H. MoskowitzPhilippe ArmandAlejandro D. RicartVincent RibragJean‐Marie MichotJohn Kuruvilla
- Partner nations
- United StatesFranceItaly
In The Last Decade
Arun Balakumaran
78 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 109
- Oncology 2.7k
- Pathology and Forensic Medicine 1.2k
- Immunology 897
- Genetics 447
- Hematology 411
Countries citing papers authored by Arun Balakumaran
This map shows the geographic impact of Arun Balakumaran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arun Balakumaran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arun Balakumaran more than expected).
Fields of papers citing papers by Arun Balakumaran
This network shows the impact of papers produced by Arun Balakumaran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arun Balakumaran. The network helps show where Arun Balakumaran may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Arun Balakumaran, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsbreakdown → | 2023 | 168 |
| 2 | Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphomabreakdown → | 2017 | 694 |
| 3 | 2017 | 1 | |
| 4 | 2017 | 3 | |
| 5 | 2016 | 1 | |
| 6 | 2016 | 1 | |
| 7 | 2016 | 41 | |
| 8 | 2016 | 46 | |
| 9 | 2015 | 22 | |
| 10 | 2015 | 2 | |
| 11 | 2015 | 27 | |
| 12 | 2014 | 2 | |
| 13 | 2014 | 2 | |
| 14 | 2013 | 120 | |
| 15 | 2010 | 19 | |
| 16 | 2010 | 17 | |
| 17 | 2010 | 83 | |
| 18 | 2004 | 4 | |
| 19 | 2000 | 50 | |
| 20 | 2000 | 7 |
About Arun Balakumaran
Arun Balakumaran is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine, having authored 78 papers that have together received 3.7k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (29 papers), Bone health and treatments (20 papers), Cancer Immunotherapy and Biomarkers (14 papers), Management of metastatic bone disease (13 papers), CAR-T cell therapy research (13 papers), Multiple Myeloma Research and Treatments (9 papers), Mesenchymal stem cell research (9 papers) and Cancer Diagnosis and Treatment (8 papers). The work is most often cited by research in Oncology (2.7k citations), Pathology and Forensic Medicine (1.2k citations) and Immunology (897 citations). Arun Balakumaran has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Pier Luigi Zinzani, Margaret A. Shipp, Craig H. Moskowitz, Philippe Armand, Alejandro D. Ricart, Vincent Ribrag, Jean‐Marie Michot, John Kuruvilla, Pamela Gehron Robey and Akihiro Tomita.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.